Compared to mice fed normal chow, those fed a Western diet had decreased total ceramide levels, decreased glucosylceramide
and nearly three times more lactosylceramide.
Furthermore, short periods of anoxia (3h) followed by reoxygenation (0-5 h) led to a time-dependent increase of caspase activity in human umbilical vein endothelial cells (HUVECs), which was associated with a significant decrease in glucosylceramide
synthase mRNA levels and protein expression, but no changes in SMase.
Cer can be converted by the glucosylceramide
synthase (GluCer-synthase) to GluCer and further to LacCer by the action of lactosylceramide synthase (LacCer-synthase).
The product is Japan's first drink that is a type of food with function claims containing glucosylceramide
derived from rice.
as its active component to make it harder for moisture to escape from the skin,(2) Chocola BB Rich Ceramide is a product that you can drink to counter dry skin.
The clinical diagnosis of GD currently relies on demonstration of a deficient lysosomal enzyme acid [sz]-glucosidase (glucocerebrosidase [GBA]) which is responsible for the hydrolysis of glucocerebroside (glucosylceramide
) into glucose and ceramide.[sup], GBA gene is the only gene in which mutations are known to cause the GD.
ET with imiglucerase has become the standard of care for treatment of significantly symptomatic Gaucher disease type 1.10,11 Eliglustat (Cerdelga) is a new oral oral glucosylceramide
synthase inhibitor indicated for the long-term treatment of adult patients with Gaucher disease type 112, It is not affordable in Iraq under the financial hardship.
This leads to the harmful accumulation of GC, which is also known as glucosylceramide
, in the lysosomes, most commonly in the macrophages and monocytes, throughout the body.
Detection of antibody against fungal glucosylceramide
in immunocompromised patients: a potential new diagnostic approach for cryptococcosis.
For those individuals with type 1 Gaucher disease, treatment may include enzyme replacement therapy (glucosylceramide
synthase inhibitors), which is indicated for the long-term treatment of adult patients.
GZ/SAR402671 is a glucosylceramide
synthase inhibitor that blocks the formation of glucosylceramide
(GL-1), a key intermediate in the synthesis of GL-3.
, the substrate for the relevant enzyme, is reported to be on average a 3-fold increase in type I Gaucher patients compared to healthy individuals (60).